Recent studies suggest that AP-1 inhibitors have shown promise in improving outcomes in various pulmonary fibrosis models, making AP-1 inhibition a novel therapeutic focus for the treatment of pulmonary fibrosis (Table 3). This evidence concerns the gene JUNB and pulmonary fibrosis.